Kahn Swick & Foti launches investigation into Nathan's Famous sale; procedural risk adds to merger arb complexity

What happened

Law firm Kahn Swick & Foti announced an investigation into the adequacy of the price and process of Nathan's Famous' proposed $102 per share all-cash sale to Smithfield Foods, citing potential breaches of fiduciary duty by the board. The deal, agreed in January 2026, remains subject to shareholder approval and HSR/CFIUS clearances, with an outside date of June 22, 2026 extendable to October 20, 2026. Such shareholder-rights investigations are relatively common after merger announcements and often do not result in litigation or deal changes, but they can prompt additional disclosures or modest delays. The stock currently trades at a tight ~1.3% spread to the deal price, reflecting high market confidence in closing, so any incremental uncertainty could widen the spread. The core investment thesis remains centered on regulatory clearance and definitive proxy mailing, making this probe a secondary procedural risk to monitor.

Implication

The investigation is a common occurrence after merger announcements and frequently leads to no substantive action, but it can lead to delays if the company must respond to discovery or issue additional proxy disclosures. Given the already tight spread, any delay increases the opportunity cost of holding the position, especially as the outside date approaches. The primary risks remain HSR and CFIUS clearance, and this probe could interact with those timelines if it forces a postponement of the shareholder vote. Investors should watch for a formal complaint or any indication the board will renegotiate terms; absent that escalation, the investment thesis is unchanged. If the probe does escalate, it could widen the spread and provide a better entry point for those willing to accept the binary regulatory risk.

Thesis delta

The core investment thesis is unchanged: Nathan's Famous is a merger arbitrage with limited upside to the $102 cash consideration and significant binary risk tied to regulatory approvals and proxy timing. The Kahn Swick & Foti investigation introduces a low-probability risk of litigation or procedural delay, but it does not alter the deal economics or the fundamental value of the company. The addition of this shareholder-rights probe reinforces the need to closely monitor procedural milestones and any disclosures related to board conduct.